Japan's NEC Expands Biopharma Presence With AI-Based R&D
Now in Norway, Netherlands and Germany
Executive Summary
Japanese tech major re-structures its teams for artificial intelligence-based drug development and strategies while expanding its presence in Europe. With confidence in the utility of AI for discovery, it is retaining a key focus on oncology while adding infectious diseases to its targets.